Wellington Management Group LLP Has $67.57 Million Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Wellington Management Group LLP raised its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 3.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,586,605 shares of the company's stock after purchasing an additional 104,500 shares during the quarter. Wellington Management Group LLP owned approximately 4.73% of Nurix Therapeutics worth $67,572,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Barclays PLC lifted its stake in shares of Nurix Therapeutics by 77.9% during the 3rd quarter. Barclays PLC now owns 128,344 shares of the company's stock worth $2,884,000 after buying an additional 56,190 shares during the last quarter. SG Americas Securities LLC lifted its position in Nurix Therapeutics by 31.1% during the fourth quarter. SG Americas Securities LLC now owns 30,086 shares of the company's stock worth $567,000 after acquiring an additional 7,141 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Nurix Therapeutics by 21.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 15,020 shares of the company's stock worth $283,000 after acquiring an additional 2,632 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in Nurix Therapeutics by 42.7% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company's stock worth $14,869,000 after acquiring an additional 235,971 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in Nurix Therapeutics by 13.5% during the fourth quarter. Rhumbline Advisers now owns 103,233 shares of the company's stock worth $1,945,000 after acquiring an additional 12,315 shares during the last quarter.

Analyst Ratings Changes

Several analysts recently weighed in on NRIX shares. Leerink Partnrs raised Nurix Therapeutics to a "hold" rating in a report on Monday, March 17th. Morgan Stanley lifted their target price on Nurix Therapeutics from $16.00 to $17.00 and gave the stock an "equal weight" rating in a report on Monday, February 3rd. Wall Street Zen cut shares of Nurix Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Stifel Nicolaus dropped their price objective on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, April 9th. Finally, Leerink Partners assumed coverage on shares of Nurix Therapeutics in a research report on Monday, March 17th. They issued a "market perform" rating and a $16.00 price target for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $30.44.

Insider Transactions at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 5,825 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the transaction, the chief financial officer now owns 33,724 shares of the company's stock, valued at $488,660.76. This represents a 14.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Gwenn Hansen sold 3,377 shares of the company's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $38,835.50. Following the completion of the transaction, the insider now directly owns 61,516 shares of the company's stock, valued at $707,434. This represents a 5.20% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 17,838 shares of company stock worth $221,500. Corporate insiders own 7.40% of the company's stock.

Nurix Therapeutics Trading Down 0.2%

NASDAQ NRIX traded down $0.02 during trading on Friday, hitting $10.62. 922,966 shares of the company's stock were exchanged, compared to its average volume of 875,710. The company has a market cap of $809.63 million, a PE ratio of -3.67 and a beta of 2.23. Nurix Therapeutics, Inc. has a fifty-two week low of $8.18 and a fifty-two week high of $29.56. The stock's 50 day moving average price is $10.35 and its two-hundred day moving average price is $15.80.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.72) by $0.05. The business had revenue of $18.45 million during the quarter, compared to analysts' expectations of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same period in the prior year, the company earned ($0.76) EPS. Analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.